- Home
- FOLD vs BBU Comparison
FOLD vs BBU Comparison
Compare FOLD & BBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- BBU
- Stock Information
- Founded
- FOLD 2002
- BBU 2016
- Country
- FOLD United States
- BBU Bermuda
- Employees
- FOLD N/A
- BBU N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- BBU Engineering & Construction
- Sector
- FOLD Health Care
- BBU Consumer Discretionary
- Exchange
- FOLD Nasdaq
- BBU Nasdaq
- Market Cap
- FOLD 2.9B
- BBU 2.4B
- IPO Year
- FOLD 2007
- BBU N/A
- Fundamental
- Price
- FOLD $7.58
- BBU $27.04
- Analyst Decision
- FOLD Strong Buy
- BBU Buy
- Analyst Count
- FOLD 10
- BBU 5
- Target Price
- FOLD $26.89
- BBU $31.80
- AVG Volume (30 Days)
- FOLD 3.8M
- BBU 23.8K
- Earning Date
- FOLD 07-31-2025
- BBU 08-01-2025
- Dividend Yield
- FOLD N/A
- BBU 0.92%
- EPS Growth
- FOLD N/A
- BBU N/A
- EPS
- FOLD N/A
- BBU N/A
- Revenue
- FOLD $571,160,000.00
- BBU $30,103,000,000.00
- Revenue This Year
- FOLD $20.98
- BBU N/A
- Revenue Next Year
- FOLD $20.74
- BBU $5.85
- P/E Ratio
- FOLD N/A
- BBU N/A
- Revenue Growth
- FOLD 25.35
- BBU N/A
- 52 Week Low
- FOLD $5.51
- BBU $18.63
- 52 Week High
- FOLD $12.65
- BBU $28.28
- Technical
- Relative Strength Index (RSI)
- FOLD 69.88
- BBU 70.78
- Support Level
- FOLD $7.40
- BBU $26.97
- Resistance Level
- FOLD $7.80
- BBU $28.28
- Average True Range (ATR)
- FOLD 0.22
- BBU 0.78
- MACD
- FOLD 0.01
- BBU 0.30
- Stochastic Oscillator
- FOLD 87.61
- BBU 93.66
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.